The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening

dc.contributor.authorJacobsen, Laura M.
dc.contributor.authorBocchino, Laura
dc.contributor.authorEvans-Molina, Carmella
dc.contributor.authorDiMeglio, Linda
dc.contributor.authorGoland, Robin
dc.contributor.authorWilson, Darrell M.
dc.contributor.authorAtkinson, Mark A.
dc.contributor.authorAye, Tandy
dc.contributor.authorRussell, William E.
dc.contributor.authorWentworth, John M.
dc.contributor.authorBoulware, David
dc.contributor.authorGeyer, Susan
dc.contributor.authorSosenko, Jay M.
dc.contributor.departmentMedicine, School of Medicineen_US
dc.date.accessioned2020-07-20T20:31:32Z
dc.date.available2020-07-20T20:31:32Z
dc.date.issued2020-03
dc.description.abstractAims/hypothesis: Young children who develop multiple autoantibodies (mAbs) are at very high risk for type 1 diabetes. We assessed whether a population with mAbs detected by screening is also at very high risk, and how risk varies according to age, type of autoantibodies and metabolic status. Methods: Type 1 Diabetes TrialNet Pathway to Prevention participants with mAbs (n = 1815; age, 12.35 ± 9.39 years; range, 1-49 years) were analysed. Type 1 diabetes risk was assessed according to age, autoantibody type/number (insulin autoantibodies [IAA], glutamic acid decarboxylase autoantibodies [GADA], insulinoma-associated antigen-2 autoantibodies [IA-2A] or zinc transporter 8 autoantibodies [ZnT8A]) and Index60 (composite measure of fasting C-peptide, 60 min glucose and 60 min C-peptide). Cox regression and cumulative incidence curves were utilised in this cohort study. Results: Age was inversely related to type 1 diabetes risk in those with mAbs (HR 0.97 [95% CI 0.96, 0.99]). Among participants with 2 autoantibodies, those with GADA had less risk (HR 0.35 [95% CI 0.22, 0.57]) and those with IA-2A had higher risk (HR 2.82 [95% CI 1.76, 4.51]) of type 1 diabetes. Those with IAA and GADA had only a 17% 5 year risk of type 1 diabetes. The risk was significantly lower for those with Index60 <1.0 (HR 0.23 [95% CI 0.19, 0.30]) vs those with Index60 values ≥1.0. Among the 12% (225/1815) ≥12.0 years of age with GADA positivity, IA-2A negativity and Index60 <1.0, the 5 year risk of type 1 diabetes was 8%. Conclusions/interpretation: Type 1 diabetes risk varies substantially according to age, autoantibody type and metabolic status in individuals screened for mAbs. An appreciable proportion of older children and adults with mAbs appear to have a low risk of progressing to type 1 diabetes at 5 years. With this knowledge, clinical trials of type 1 diabetes prevention can better target those most likely to progress.en_US
dc.eprint.versionAuthor's manuscripten_US
dc.identifier.citationJacobsen, L. M., Bocchino, L., Evans-Molina, C., DiMeglio, L., Goland, R., Wilson, D. M., Atkinson, M. A., Aye, T., Russell, W. E., Wentworth, J. M., Boulware, D., Geyer, S., & Sosenko, J. M. (2020). The risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screening. Diabetologia, 63(3), 588–596. https://doi.org/10.1007/s00125-019-05047-wen_US
dc.identifier.urihttps://hdl.handle.net/1805/23286
dc.language.isoen_USen_US
dc.publisherSpringer Verlagen_US
dc.relation.isversionof10.1007/s00125-019-05047-wen_US
dc.relation.journalDiabetologiaen_US
dc.rightsPublisher Policyen_US
dc.sourcePMCen_US
dc.subjectAgeen_US
dc.subjectAutoantibodiesen_US
dc.subjectIndex60en_US
dc.subjectMetabolicen_US
dc.subjectType 1 diabetesen_US
dc.titleThe risk of progression to type 1 diabetes is highly variable in individuals with multiple autoantibodies following screeningen_US
dc.typeArticleen_US
Files
Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
nihms-1581467.pdf
Size:
529.67 KB
Format:
Adobe Portable Document Format
Description:
Main article
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.99 KB
Format:
Item-specific license agreed upon to submission
Description: